Vascular Graft Infections With Candida: A Factor for Increased Mortality in in-situ Reconstructions.


Journal

Annals of vascular surgery
ISSN: 1615-5947
Titre abrégé: Ann Vasc Surg
Pays: Netherlands
ID NLM: 8703941

Informations de publication

Date de publication:
May 2022
Historique:
received: 12 07 2021
revised: 03 11 2021
accepted: 06 11 2021
pubmed: 14 12 2021
medline: 11 5 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

The empiric antibiotic regimen started after deep cultures and explantation of the graft mostly do not cover antifungals. We retrospectively studied the outcome of candida compared to non-candida VGI and assessed whether these results could justify the addition of antifungals to the empiric antibiotics in the early postoperative period. All patients treated for infected aorto(ilio)femoral graft with excision and reconstruction at the vascular department of University Hospitals Leuven between January 2010 and 2017 (n = 56) were studied retrospectively. Patients were allocated to the candida group (n = 10) or non-candida group (n = 46) according to the presence of Candida in deep culture isolates. All-cause mortality was significantly higher in the candida group compared to the non-candida group. All-cause 30-day mortality was 40% and 13% for both groups respectively (P = 0.066). At 5 years this was 90% and 46% respectively (P = 0.014). In the candida group 6 patients (60%) had to be revised in the operating room due to bleeding, compared to 5 patients (11%) in the non-candida group (P = 0.002).  Two patients (20%) and 5 patients (11%) had to be readmitted to the ICU, respectively. Survival of candida related VGI is significantly worse, especially in the first 5 postoperative months. This could justify the addition of an antifungal to the early empiric postoperative antibiotic cocktail, especially in patients with an aorto-enteric fistula. A cost-benefit analysis could be useful to evaluate the yield.

Sections du résumé

BACKGROUND BACKGROUND
The empiric antibiotic regimen started after deep cultures and explantation of the graft mostly do not cover antifungals. We retrospectively studied the outcome of candida compared to non-candida VGI and assessed whether these results could justify the addition of antifungals to the empiric antibiotics in the early postoperative period.
METHODS METHODS
All patients treated for infected aorto(ilio)femoral graft with excision and reconstruction at the vascular department of University Hospitals Leuven between January 2010 and 2017 (n = 56) were studied retrospectively. Patients were allocated to the candida group (n = 10) or non-candida group (n = 46) according to the presence of Candida in deep culture isolates.
RESULTS RESULTS
All-cause mortality was significantly higher in the candida group compared to the non-candida group. All-cause 30-day mortality was 40% and 13% for both groups respectively (P = 0.066). At 5 years this was 90% and 46% respectively (P = 0.014). In the candida group 6 patients (60%) had to be revised in the operating room due to bleeding, compared to 5 patients (11%) in the non-candida group (P = 0.002).  Two patients (20%) and 5 patients (11%) had to be readmitted to the ICU, respectively.
CONCLUSION CONCLUSIONS
Survival of candida related VGI is significantly worse, especially in the first 5 postoperative months. This could justify the addition of an antifungal to the early empiric postoperative antibiotic cocktail, especially in patients with an aorto-enteric fistula. A cost-benefit analysis could be useful to evaluate the yield.

Identifiants

pubmed: 34902469
pii: S0890-5096(21)00929-8
doi: 10.1016/j.avsg.2021.11.004
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antifungal Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-211

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Dries Dorpmans (D)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Karen Peeters (K)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Hozan Mufty (H)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium.

Yves Debaveye (Y)

Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.

Eric Van Wijngaerden (E)

Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.

Inge Fourneau (I)

Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium. Electronic address: inge.fourneau@uzleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH